Sanofi (NASDAQ: SNY)
Sanofi Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sanofi Company Info
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
News & Analysis
Why Sanofi Stock Flew Higher on Friday
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Why Sanofi Stock Was Robustly Healthy Today
Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.
Sanofi's New Drug Could Deliver a Big Payday
Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
This Stock Just Dropped By 15%: Is It a Buy?
Now could be a great opportunity to buy low.
2 Surefire Stocks That Could Make You Richer
It won't happen overnight, but with these stocks, a little patience is all you need.
2 Biotech Stocks That Could Make You Richer
Neither is performing particularly well this year compared to the broader market, but don't let that chase you away.
Was This $3 Billion Deal a Wise Move for Sanofi?
The French drugmaker appears to have meaningfully improved its portfolio with the acquisition.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.